Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK2 | P49760 | 3/20 | 0.60 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.60 |
| ▸ | MAPK9 | P45984 | 3/20 | 0.60 |
| ▸ | GAK | O14976 | 1/20 | 0.60 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.60 |
| ▸ | JAK2 | O60674 | 1/20 | 0.60 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.60 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.60 |
| ▸ | NQO2 | P16083 | 1/20 | 0.60 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.60 |
| ▸ | FECH | P22830 | 1/20 | 0.60 |
| ▸ | JAK1 | P23458 | 1/20 | 0.60 |
| ▸ | TYK2 | P29597 | 1/20 | 0.60 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.60 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.60 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.60 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.60 |
| ▸ | CLK1 | P49759 | 1/20 | 0.60 |
| ▸ | GSK3B | P49841 | 1/20 | 0.60 |
| ▸ | JAK3 | P52333 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cc-401 SCHEMBL4607855 | 0.91 | CLK2 (0.72) | CLK2DYRK1AMAPK9GAKDYRK3 | |
| SCHEMBL5395180 | 0.90 | CLK2 (0.61) | CLK2DYRK1AMAPK9GAKDYRK3 | |
| SCHEMBL8268334 | 0.86 | CLK2 (0.57) | CLK2DYRK1AMAPK9GAKDYRK3 | |
| Cc-401 SCHEMBL5960126 | 0.86 | DYRK1A (0.66) | CLK2DYRK1AMAPK9GAKDYRK3 | |
| SCHEMBL5387438 | 0.85 | CLK2 (0.56) | CLK2DYRK1AMAPK9GAKDYRK3 | |
| SCHEMBL5377755 | 0.84 | CLK2 (0.83) | CLK2DYRK1AMAPK9GAKDYRK3 | |
| SCHEMBL5377883 | 0.84 | CLK2 (0.63) | CLK2DYRK1AMAPK9GAKDYRK3 | |
| SCHEMBL6506876 | 0.84 | DYRK1A (0.58) | CLK2DYRK1AMAPK9GAKDYRK3 | |
| SCHEMBL5377612 | 0.83 | CLK2 (0.53) | CLK2DYRK1AMAPK9GAKDYRK3 | |
| SCHEMBL4080252 | 0.82 | CLK2 (0.58) | CLK2DYRK1AMAPK9GAKDYRK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170327788-A1 | COMPOSITION FOR COLLECTING AND PRESERVING PLACENTAL STEM CELLS AND METHODS OF USING THE COMPOSITION | ANTHROGENESIS CORPORATION (US) | 2017-11-16 | — | — | US | disclosed |
| US-9725694-B2 | Composition for collecting and preserving placental stem cells and methods of using the composition | ANTHROGENESIS CORPORATION (US) | 2017-08-08 | — | — | US | disclosed |
| US-9725694-B2 | Composition for collecting and preserving placental stem cells and methods of using the composition | ANTHROGENESIS CORPORATION (US) | 2017-08-08 | — | — | US | disclosed |
| US-9598669-B2 | Composition for collecting placental stem cells and methods of using the composition | ANTHROGENESIS CORPORATION (US) | 2017-03-21 | — | — | US | disclosed |
| US-9598669-B2 | Composition for collecting placental stem cells and methods of using the composition | ANTHROGENESIS CORPORATION (US) | 2017-03-21 | — | — | US | disclosed |
| US-20100291679-A1 | COMPOSITION FOR COLLECTING AND PRESERVING PLACENTAL STEM CELLS AND METHODS OF USING THE COMPOSITION | ANTHROGENESIS CORPORATION | 2010-11-18 | — | — | US | disclosed |
| US-20100291679-A1 | COMPOSITION FOR COLLECTING AND PRESERVING PLACENTAL STEM CELLS AND METHODS OF USING THE COMPOSITION | ANTHROGENESIS CORPORATION | 2010-11-18 | — | — | US | disclosed |
| WO-2008091925-A2 | TREATMENT OF AORTIC DISSECTION OR ANEURYSM | COOK INCORPORATED (US) | 2008-07-31 | — | — | WO | disclosed |
| US-20070270448-A1 | Methods of Using and Compositions Comprising a Jnk Inhibitor for the Treatment and Management of Asbestos-Related Diseases and Disorders | CELGENE CORPORATION (US) | 2007-11-22 | — | — | US | disclosed |
| US-20070270448-A1 | Methods of Using and Compositions Comprising a Jnk Inhibitor for the Treatment and Management of Asbestos-Related Diseases and Disorders | CELGENE CORPORATION (US) | 2007-11-22 | — | — | US | disclosed |
| EP-1525308-A4 | METHODS OF USING JNK OR MKK INHIBITORS TO MODULATE CELL DIFFERENTIATION AND TO TREAT MYELOPROLIFERATIVE DISORDERS AND MYELODYSPLASTIC SYNDROMES | CELGENE CORP (US) | 2006-11-02 | — | — | EP | disclosed |
| WO-2006058007-A2 | JNK INHIBITORS FOR TREATMENT OF CNS INJURY | CELGENE CORPORATION (US) | 2006-06-01 | — | — | WO | disclosed |
| WO-2006058007-A2 | JNK INHIBITORS FOR TREATMENT OF CNS INJURY | CELGENE CORPORATION (US) | 2006-06-01 | — | — | WO | disclosed |
| EP-1525308-A2 | METHODS OF USING JNK OR MKK INHIBITORS TO MODULATE CELL DIFFERENTIATION AND TO TREAT MYELOPROLIFERATIVE DISORDERS AND MYELODYSPLASTIC SYNDROMES | CELGENE CORPORATION (US) | 2005-04-27 | — | — | EP | disclosed |
| WO-2004041191-A2 | METHODS FOR THE TREATMENT, PREVENTION AND MANAGEMENT OF MACULAR DEGENERATION | CELGENE CORPORATION (US) | 2004-05-21 | — | — | WO | disclosed |
| US-20040087642-A1 | Methods of using and compositions comprising a JNK inhibitor for the treatment, prevention, management and/or modification of pain | CELGENE CORPORATION | 2004-05-06 | — | — | US | disclosed |
| US-20040087642-A1 | Methods of using and compositions comprising a JNK inhibitor for the treatment, prevention, management and/or modification of pain | CELGENE CORPORATION | 2004-05-06 | — | — | US | disclosed |
| WO-2003102151-A2 | MODULATING CELL DIFFERENTIATION AND TREATING MYELOPROLIFERTIVE DISORDERS WITH JNK/MKK INHIBITORS | CELGENE CORPORATION (US) | 2003-12-11 | — | — | WO | disclosed |
| WO-2003102151-A2 | MODULATING CELL DIFFERENTIATION AND TREATING MYELOPROLIFERTIVE DISORDERS WITH JNK/MKK INHIBITORS | CELGENE CORPORATION (US) | 2003-12-11 | — | — | WO | disclosed |
| WO-2003099221-A2 | METHODS FOR USING JNK INHIBITORS FOR TREATING OR PREVENTING DISEASE-RELATED WASTING | SIGNAL PHARMACEUTICALS, INC. (US) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087642-A1 | Methods of using and compositions comprising a JNK inhibitor for the treatment, prevention, management and/or modification of pain | MAP3K1, MAP3K6, MAPKAPK2 | CLK2 340/4885DYRK1A 769/4885MAPK9 59/4885 |
| US-20070270448-A1 | Methods of Using and Compositions Comprising a Jnk Inhibitor for the Treatment and Management of Asbestos-Related Diseases and Disorders | MAP3K6, MAP3K1, MAPK1 | CLK2 572/4885DYRK1A 404/4885MAPK9 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.